The US FDA has approved Pfizer’s vaccine Penbraya for ages 10 to 25, offering protection against the five main types of bacteria causing meningitis and blood poisoning. As a two-dose vaccine administered six months apart, it combines elements of Trumenba and Menveo and reduces the current four-dose regimen for full protection. The CDC will discuss recommendations for Penbraya’s use in adolescents and young adults.
Majority of Organizations Agree That Many GRC AI Tools Aren't Ready
A report by Drata recently analyzed survey responses from security and IT professionals on AI adoption trends.
